tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Promising Pipeline Developments and Strategic Shift Justify Buy Rating for Arvinas Holding Company
PremiumRatingsPromising Pipeline Developments and Strategic Shift Justify Buy Rating for Arvinas Holding Company
2M ago
Arvinas Reports Q3 2025 Earnings and Strategic Progress
Premium
Company Announcements
Arvinas Reports Q3 2025 Earnings and Strategic Progress
2M ago
Arvinas Earnings Call: Promising Pipeline Amid Revenue Challenges
Premium
Company Announcements
Arvinas Earnings Call: Promising Pipeline Amid Revenue Challenges
2M ago
Arvinas Advances in KRAS G12D Mutation Treatment with ARV-806 Study
PremiumCompany AnnouncementsArvinas Advances in KRAS G12D Mutation Treatment with ARV-806 Study
2M ago
Arvinas’ ARV-393: A New Hope in Non-Hodgkin’s Lymphoma Treatment?
Premium
Company Announcements
Arvinas’ ARV-393: A New Hope in Non-Hodgkin’s Lymphoma Treatment?
2M ago
Arvinas Unveils Promising Preclinical Data for ARV-806
Premium
Company Announcements
Arvinas Unveils Promising Preclinical Data for ARV-806
2M ago
Cautious Outlook for Arvinas Holding: Hold Rating Amid Uncertain Commercial Strategy for Vepdegestrant
PremiumRatingsCautious Outlook for Arvinas Holding: Hold Rating Amid Uncertain Commercial Strategy for Vepdegestrant
2M ago
Arvinas price target raised to $16 from $14 at Piper Sandler
Premium
The Fly
Arvinas price target raised to $16 from $14 at Piper Sandler
3M ago
Arvinas price target raised to $12 from $10 at BofA
Premium
The Fly
Arvinas price target raised to $12 from $10 at BofA
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100